Schlumberger: Q2 Earnings Snapshot
The The Hague, Netherlands-based company said it had profit of 74 cents per share.
The results topped Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for earnings of 73 cents per share.
The world's largest oilfield services company posted revenue of $8.55 billion in the period, which also topped Street forecasts. Nine analysts surveyed by Zacks expected $8.49 billion.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SLB at https://www.zacks.com/ap/SLB
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
StoneCo (STNE) Slashes 11.63% Ahead of Q2
We recently published StoneCo Ltd. (NASDAQ:STNE) is one of this week's top performers. StoneCo fell by 11.63 percent week-on-week to end Friday's trading at $13.67 versus the $15.47 finish on July 11, as investors repositioned portfolios ahead of the release of its second quarter earnings performance. In a statement earlier this month, StoneCo Ltd. (NASDAQ:STNE) said it will announce the results of its earnings on August 7 after market close, to be followed by a conference call at 5 PM Eastern Time. In the first quarter of the year, StoneCo Ltd. (NASDAQ:STNE) saw net income increase by 38.3 percent to R$516.7 million from R$373.6 million in the same period last year. Total revenues rose by 19 percent to R$3.669 billion from R$3.084 billion year-on-year. A team of software engineers in a digital workspace collaborating on a financial technology software solution. For the second quarter, Zacks Research expects StoneCo Ltd. (NASDAQ:STNE) to post earnings of $0.34 per share, or a 13.33 percent growth year-on-year. Meanwhile, full-year EPS was pegged at $1.44 with revenues of $2.73 billion, representing growth of 6.67 percent and 10.94 percent, respectively. While we acknowledge the potential of STNE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Schlumberger (SLB) Dives 10.69% as Earnings Disappoint
We recently published Schlumberger Limited (NYSE:SLB) is one of this week's top performers. Schlumberger saw its share prices decrease by 10.69 percent week-on-week from $37.31 on July 11 to $33.32 last Friday, as investor sentiment was dampened by a disappointing earnings performance in the second quarter of the year. In its earnings release, Schlumberger Limited (NYSE:SLB) said attributable net income, excluding charges and credits, fell by 17 percent to $1.016 billion from $1.224 billion in the same period last year. Revenues dropped by 6 percent to $8.546 billion from $9.139 billion year-on-year. An aerial view of a well site, depicting the scale of oil and gas operations. Schlumberger Limited (NYSE:SLB) regarded its performance as 'solid,' saying that it leveraged its diversified portfolio and broad market exposure to deliver steady revenues despite the market navigating several dynamics and macroeconomic uncertainties. 'Despite this, commodity prices have remained range-bound. Meanwhile, customers have selectively adjusted activity, prioritizing key projects and planning cautiously, particularly in offshore deepwater markets,' it said. While we acknowledge the potential of SLB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Life sciences VC Omega Funds closes $647m funding round
Life sciences venture capital (VC) company Omega Funds has closed its eighth fund, with capital commitments totalling $647m. As with its previous funds, the US-based business said its oversubscribed funding, which had initially targeted a $600m close, will continue executing on its strategy to support management teams in the US and Europe that target severe, unmet medical needs through company creation, early venture rounds, and later-stage financing. Omega Funds managing director Francesco Draetta said: 'We believe our broad investment strategy is well-positioned for navigating this period of macro and policy uncertainty. 'We look forward to contributing our capital, expertise, and network connectivity in partnering with entrepreneurs, founders, co-investors, and the broader community to transform the standards of care for severe diseases.' According to Omega, it has raised $2.5bn since its first fund in 2004 to support the development of medical devices and therapeutics across indications including oncology, immunology, and rare diseases. In total, 52 products have been brought to market by Omega's former portfolio companies, with the VC's previous investments resulting in 50 exits via M&A, and 47 public listings. M&A exits include SoniVie, Scorpion Therapeutics, and Amunix Pharmaceuticals, which were acquired by Boston Scientific, Eli Lilly, and Sanofi, respectively. Companies that Omega has invested in have gone on to launch initial public offerings (IPO). These include Kestra Medical Technologies, Beta Bionics, and Imago Biosciences, all of which are listed on the Nasdaq exchange. Omega Funds' founder and managing director Otello Stampacchia commented: 'By exceeding its target size, fund VIII is a recognition of our investment strategy and track record of consistent exits across market cycles.' Life science companies are typically reliant on investment from VC or private equity (PE) businesses. While research by Bain & Company found that deal value in 2023 struggled to match the pace of previous years, more recent research by the consultant found that healthcare PE soared to an estimated $115bn in 2024, making it the second-highest deal value total on record. Other significant entities backing life science companies include Symbiotic Capital. The credit company from biotech entrepreneur Arie Belldegrun, founder of Kite Pharma and co-founder of Bellco Capital, launched in August 2024 with $600m for life science-specific loans. "Life sciences VC Omega Funds closes $647m funding round" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
